scholarly article | Q13442814 |
P50 | author | Sergio Giralt | Q66764444 |
Edward A. Stadtmauer | Q85544110 | ||
Luciano J Costa | Q88251235 | ||
P2093 | author name string | Elizabeth E Brown | |
Amrita Y Krishnan | |||
Parameswaran Hari | |||
Francesca Patriarca | |||
Andrea Evangelista | |||
Benedetto Bruno | |||
Marcelo C Pasquini | |||
Gösta Gahrton | |||
Riddhi Modi | |||
Joan Blade | |||
Luisa Giaccone | |||
Simona Iacobelli | |||
Jose A Perez-Simon | |||
Laura Rosinol | |||
Stefan Schonland | |||
P2860 | cites work | Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients | Q33402680 |
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. | Q34241661 | ||
International staging system for multiple myeloma | Q34408882 | ||
A comparison of allografting with autografting for newly diagnosed myeloma | Q34577703 | ||
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research | Q35031141 | ||
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma | Q35651684 | ||
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial | Q36725446 | ||
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group | Q36839385 | ||
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. | Q37282307 | ||
Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment | Q38042273 | ||
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome | Q40752336 | ||
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. | Q44616173 | ||
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. | Q45361447 | ||
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival | Q47566330 | ||
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. | Q49504538 | ||
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. | Q51395943 | ||
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. | Q52912068 | ||
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres | Q57904065 | ||
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma | Q61803948 | ||
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation | Q68016829 | ||
Graft-versus-myeloma effect | Q71264400 | ||
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma | Q76376753 | ||
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma | Q79696686 | ||
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol | Q81168226 | ||
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma | Q81606574 | ||
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma | Q82192536 | ||
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial | Q84401841 | ||
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up | Q84509627 | ||
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma | Q88528165 | ||
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial | Q91397924 | ||
P577 | publication date | 2020-04-14 | |
P1433 | published in | Bone Marrow Transplantation | Q4941523 |
P1476 | title | Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation |
Q97866962 | Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT | cites work | P2860 |
Search more.